176 related articles for article (PubMed ID: 31817815)
1. The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The "Hemodynamic Recovery".
Romano G; Vitale G; Ajello L; Agnese V; Bellavia D; Caccamo G; Corrado E; Di Gesaro G; Falletta C; La Franca E; Minà C; Storniolo SA; Sarullo FM; Clemenza F
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817815
[TBL] [Abstract][Full Text] [Related]
2. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
4. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
[TBL] [Abstract][Full Text] [Related]
5. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
Liu LW; Wu PC; Chiu MY; Tu PF; Fang CC
Acta Cardiol Sin; 2020 Mar; 36(2):125-132. PubMed ID: 32201463
[TBL] [Abstract][Full Text] [Related]
7. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.
Gregorietti V; Fernandez TL; Costa D; Chahla EO; Daniele AJ
Cardiooncology; 2020 Nov; 6(1):24. PubMed ID: 33292750
[TBL] [Abstract][Full Text] [Related]
8. Does sacubitril/valsartan work in children with heart failure?-a pilot study.
Xu Y; Zhang M; Chen Y; Chen X; Song W; Zhu L; Liu L; Gong X; Zhang Y; Xu Z
Front Cardiovasc Med; 2023; 10():1274990. PubMed ID: 38094112
[TBL] [Abstract][Full Text] [Related]
9. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Desai AS; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; McCague K; Abbas CA; Rocha R; Mitchell GF;
JAMA; 2019 Sep; 322(11):1077-1084. PubMed ID: 31475296
[TBL] [Abstract][Full Text] [Related]
10. Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis.
Fu S; Xu Z; Lin B; Chen J; Huang Q; Xu Y; Xu A; Chen Y; Tang Y
Front Med (Lausanne); 2021; 8():657067. PubMed ID: 34235161
[No Abstract] [Full Text] [Related]
11. Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study.
Armentaro G; D'Arrigo G; Magurno M; Toscani AF; Condoleo V; Miceli S; Cassano V; Maio R; Arturi F; Tripepi G; Sesti G; Sciacqua A
Front Pharmacol; 2021; 12():733475. PubMed ID: 34483943
[TBL] [Abstract][Full Text] [Related]
12. Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction.
Vitale G; Romano G; Di Franco A; Caccamo G; Nugara C; Ajello L; Storniolo S; Sarullo S; Agnese V; Giallauria F; Novo G; Clemenza F; Sarullo FM
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30791533
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction.
Jiang J; Gao J; Zhang X; Li Y; Dang H; Liu Y; Chen W
Front Cardiovasc Med; 2023; 10():1097066. PubMed ID: 37034349
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data.
Frey MK; Arfsten H; Pavo N; Han E; Kastl S; Hülsmann M; Gyöngyösi M; Bergler-Klein J
Cardiooncology; 2021 Oct; 7(1):35. PubMed ID: 34645527
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences.
Castrichini M; Manca P; Nuzzi V; Barbati G; De Luca A; Korcova R; Stolfo D; Lenarda AD; Merlo M; Sinagra G
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32218231
[TBL] [Abstract][Full Text] [Related]
16. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction.
Xie B; Gao Q; Wang Y; Du J; He Y
Am J Transl Res; 2024; 16(5):1935-1944. PubMed ID: 38883372
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.
Pastore MC; Mandoli GE; Giannoni A; Benfari G; Dini FL; Pugliese NR; Taddei C; Correale M; Brunetti ND; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; Degiovanni A; Patti G; Santoro C; Moderato L; Malagoli A; Emdin M; Cameli M; ; Rosa G; Magnesa M; Mazzeo P; De Carli G; Bellino M; Iuliano G; Casciano O; Binno S; Canepa M; Tondi S; Cicoira M; Mega S
Eur Heart J Open; 2022 Jan; 2(1):oeab046. PubMed ID: 35919657
[TBL] [Abstract][Full Text] [Related]
18. The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report.
Gerges F; Komaranchath A; Al Bakshy F; Almaghraby A
Eur Heart J Case Rep; 2021 Feb; 5(2):ytaa530. PubMed ID: 33738400
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review.
Pascual-Figal D; Bayés-Genis A; Beltrán-Troncoso P; Caravaca-Pérez P; Conde-Martel A; Crespo-Leiro MG; Delgado JF; Díez J; Formiga F; Manito N
Front Cardiovasc Med; 2021; 8():754499. PubMed ID: 34859070
[TBL] [Abstract][Full Text] [Related]
20. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients.
Almufleh A; Marbach J; Chih S; Stadnick E; Davies R; Liu P; Mielniczuk L
Am J Cardiovasc Dis; 2017; 7(6):108-113. PubMed ID: 29348971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
